Objective:

To evaluate the efficacy of gildeuretinol in preserving vision and slowing anatomic progression in children and adolescents with early-stage Stargardt disease, focusing on primary outcome measures such as visual acuity and ellipsoid zone area.

Key Findings:

• Stable visual acuity observed in gildeuretinol-treated patients over 24 months, with a specific percentage of patients maintaining their vision.
• Slower anatomic degeneration indicated by reduced ellipsoid zone area loss compared to historical sibling data, with quantifiable metrics.
• No serious adverse events reported; treatment well-tolerated, with minor variations in systemic monitoring.

Interpretation:

Gildeuretinol appears to effectively stabilize vision and slow retinal degeneration in early-stage Stargardt disease, offering a promising treatment avenue.

Limitations:

• Small sample size of only 6 patients with 5 completing 24 months of treatment, which may limit the generalizability of the findings.
• Challenges in recruitment due to the rarity of Stargardt disease and sibling pair identification.

Conclusion:

Gildeuretinol shows potential as a treatment to slow progression of Stargardt disease, warranting further investigation in ongoing and future studies, particularly with larger sample sizes.